Journal of Endocrinological Investigation

, Volume 35, Issue 2, pp 215–218 | Cite as

Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals

  • A. Mantovani
  • G. Zoppini
  • G. Targher
  • G. Golia
  • E. Bonora
Original Article


Background: Non-alcoholic fatty liver disease (NAFLD) and left ventricular hypertrophy (LVH) are highly prevalent in Type 2 diabetes and both conditions are associated with an increased risk of incident cardiovascular disease. The aim of this study is to evaluate whether there is an association between NAFLD and echocardiographically detected LVH in Type 2 diabetes. Methods: We studied 116 consecutive patients with hypertension and Type 2 diabetes after excluding those with pre-existing history of cardiovascular disease, advanced kidney disease, excessive alcohol consumption and other known causes of chronic liver disease (e.g., virus, medications, autoimmunity, iron overload). NAFLD was diagnosed by means of ultrasonography, whereas LVH was diagnosed by means of conventional trans-thoracic echocardiography in all patients. Results: The prevalence of LVH was markedly higher among diabetic patients with NAFLD than among those without this disease (82% vs 18%; p=0.01). Multivariate logistic regression analysis revealed that NAFLD was associated with LVH independently of age, sex, body mass index, systolic blood pressure, glycated hemoglobin, duration of diabetes, and parameters of kidney function. Conclusions: Our findings suggest that hypertensive Type 2 diabetic patients with NAFLD have a remarkably higher frequency of LVH than do hypertensive diabetic patients without steatosis, and that NAFLD is associated with LVH independently of classical cardiovascular risk factors and other potential confounders.


Cardiovascular risk factors diabetes hypertension left ventricular hypertrophy non-alcoholic fatty liver disease 


  1. 1.
    de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008, 48(Suppl 1): S104–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009, 49: 306–17.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008, 93(Suppl 1): S74–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999, 84: 1513–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191: 235–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006, 43: 1145–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women’s Heart and Health Study and meta-analysis. Arterioscler Thromb Vasc Biol 2007, 27: 2729–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998, 31: 1635–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322: 1561–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006; 40: 949–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Fallo F, Dalla Pozza A, Sonino N, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009, 19: 646–53.PubMedCrossRefGoogle Scholar
  12. 12.
    Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK. Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 1997, 29: 641–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006, 354: 2473–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363: 1341–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Verdecchia P, Angeli F, Achilli P, et al. Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events? Curr Opin Cardiol 2007, 22: 329–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008, 21: 500–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens 2006, 19: 493–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006, 296: 1242–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Degertekin B, Ozenirler S, Elbeg S, Akyol G. The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci 2007, 52: 2622–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Yokohama S, Tokusashi Y, Nakamura K, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006, 12: 322–6.PubMedGoogle Scholar
  21. 21.
    Hyogo H, Yamagishi S, Iwamoto K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22: 1112–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Fallo F, Dalla Pozza A, Tecchio M, et al. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. Am J Hypertens 2010, 23: 2–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009, 35: 277–87.PubMedCrossRefGoogle Scholar
  24. 24.
    Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 1999, 42: 246–53.PubMedCrossRefGoogle Scholar
  25. 25.
    Davis CL, Kapuku G, Snieder H, Kumar M, Treiber FA. Insulin resistance syndrome and left ventricular mass in healthy young people. Am J Med Sci 2002, 324: 72–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Vaccaro O, Cardoni O, Cuomo V, et al; Gubbio Study Research Group. Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio Study. Clin Endocrinol (Oxf) 2003, 58: 316–22.CrossRefGoogle Scholar
  27. 27.
    Iacobellis G, Ribaudo MC, Zappaterreno A, et al. Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. Obes Res 2003, 11: 518–24.PubMedCrossRefGoogle Scholar
  28. 28.
    Sasson Z, Rasooly Y, Bhesania T, Rasooly I. Insulin resistance is an important determinant of left ventricular mass in the obese. Circulation 1993, 88: 1431–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008, 14: 3476–83.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2012

Authors and Affiliations

  • A. Mantovani
    • 1
  • G. Zoppini
    • 1
  • G. Targher
    • 1
  • G. Golia
    • 2
  • E. Bonora
    • 1
  1. 1.Division of Endocrinology and Metabolism, Department of MedicineUniversity of Verona Medical SchoolVeronaItaly
  2. 2.Division of Cardiology, Department of MedicineUniversity of Verona Medical SchoolVeronaItaly

Personalised recommendations